Ribo Life Science

Cardiovascular, metabolic, and kidney diseases share risk factors and pathological pathways. Metabolic disorders, such as elevated cholesterol and triglycerides, accelerate atherosclerosis and thrombosis. Chronic kidney disease (e.g., IgA nephropathy) often co-occurs with metabolic dysfunction, increasing cardiovascular risks. Studies show 60–80% of chronic kidney disease patients also have hypertriglyceridemia (HTG), worsening kidney damage. Triglyceride levels above 200 mg/dL triple the risk of kidney function decline.

RiboBio advances key small nucleic acid drug technologies. Its RiboGalSTARTM liver-targeting delivery system achieves precise hepatic delivery, while RiboOncoSTARTM targets extrahepatic tumors. RiboPepSTARTM is being developed for kidney, central nervous system, fat, and muscle tissue targeting. The company also progresses in siRNA chemical modification and multi-target drug platforms, enhancing efficacy, specificity, and therapeutic potential.

As an early pioneer in nucleic acid technology, RiboBio holds a robust global intellectual property portfolio covering siRNA sequences, chemical modifications, delivery technologies, molecular structures, combination therapies, and clinical applications. As of June 2026, it owns 493 patents and applications (260 granted, 233 pending) across China, Europe, the United States, and Japan, safeguarding its technological and drug assets.

Cardiovascular, metabolic, kidney, and liver diseases affect millions globally. RiboBio’s innovations aim to deliver more precise, effective, and accessible treatments for patients.

The study examines the effects of the oligonucleotide drug RBD8088 in mouse models of human glioblastoma.

RiboBio recently received two prestigious awards: it was named one of China’s top 50 most investable healthcare companies at the 2026 Future Healthcare & Pharmaceutical 100 Summit and recognized as a ‘World Finance Forum Technology Innovation Leader’ at the 2026 World Finance Forum Annual Conference. These honors reflect industry and market validation of its innovation, platform, pipeline, and commercial potential as a leader in China’s small nucleic acid sector.

RiboBio completed a private equity funding round exceeding 200 million RMB, led by Mingxin Capital, with participation from Kunshan High-Tech Investment, Kunshan Guoke Investment, Chouqin Investment, Panlin Capital, Langmafeng Investment, and Shenzhen Xincheng Medical. The funds will accelerate clinical pipeline development in cardiovascular, metabolic, kidney, and liver diseases, advance liver-targeting delivery technology, and strengthen global R&D and industrial capabilities.

In January 2026, RiboBio officially listed on the Hong Kong Stock Exchange’s main board (stock code: 06938.HK), marking a capitalization milestone for China’s siRNA innovation drug sector.

RiboBio offers employees a comprehensive growth pathway from junior to senior management, with customized training programs to develop expertise and leadership skills in global biopharmaceuticals.

Jia Jidong serves as chief physician, professor, and doctoral supervisor at the Capital Medical University Beijing Friendship Hospital’s Liver Disease Research Center. He holds multiple leadership roles, including president of the Liver Disease Committee under the Chinese Medical Doctor Association’s Gastroenterology Division and vice-chairman of the Chinese Hepatitis Prevention and Treatment Foundation.

RiboBio focuses on developing RNA interference (RNAi) technology and commercializing small nucleic acid drugs. It was among the earliest global pioneers in this field and listed on the Hong Kong Stock Exchange’s main board in January 2026 (stock code: 06938.HK). The company has built an autonomous, fully integrated small nucleic acid drug R&D platform and a global development system, with pipelines targeting cardiovascular, metabolic, kidney, and liver diseases.

RiboBio is a key innovator in RNAi drug development, with an autonomous small nucleic acid R&D platform. Its proprietary GalNAc delivery technology, RiboGalSTARTM, achieves high liver specificity and sustained efficacy. The company’s pipelines target cardiovascular-metabolic diseases, liver disease, kidney disease, and rare disorders, aiming for global market expansion and RNAi therapeutic advancements.

RiboBio respects user privacy and requires individuals to review its privacy policy before submitting personal data.